CN106390131A - Western medicine composition for treating rheumatic bone disease - Google Patents
Western medicine composition for treating rheumatic bone disease Download PDFInfo
- Publication number
- CN106390131A CN106390131A CN201611078004.7A CN201611078004A CN106390131A CN 106390131 A CN106390131 A CN 106390131A CN 201611078004 A CN201611078004 A CN 201611078004A CN 106390131 A CN106390131 A CN 106390131A
- Authority
- CN
- China
- Prior art keywords
- parts
- western medicine
- bone disease
- medicine compound
- gains
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
Abstract
The invention discloses a Western medicine composition for treating rheumatic bone disease. The Western medicine composition contains the following raw materials in parts by weight: 2-15 parts of Amprenavir, 0.1-1 part of methotrexate, 1-3 parts of oxaliplatin mannitol injection, 0.1-1 part of phosphodiesterase, 1-5 parts of glucocorticoid drug, 0.5-2 parts of etanercept, 10-50 parts of normal saline, 0.5-1 part of ossotide tablets, 1-3 parts of donkey-hide gelatin powder, 0.1-1 part of steroid and 1-3 parts of anisodamine. By compounding the raw materials to realize a synergistic effect, the Western medicine composition has the advantages of few toxic and side effects, low cost and no complications and can realize thorough and radical treatment of rheumatic bone disease while the rheumatic bone disease does not relapse easily; and moreover, the Western medicine composition is easy to prepare, has a short treatment cycle, has a good treatment effect and is a safe and effective medicine which protects the health of people.
Description
Technical field
The present invention relates to rheumatism bone disease treatment technology field, specifically a kind of Western medicine compound treating rheumatism bone disease.
Background technology
The blood circulation that rheumatism bone disease causes mainly due to chill is obstructed, causes including flesh, ligament, synovial bursa, manadesma
The bad disease leading to of nutrition supply.Arthropathy in addition to having pain still with swelling and moving obstacle, in outbreak with alleviate
The alternately chronic course of disease, some patientss and may occur in which to disable and viscera function exhaustion in joint.In recent years, rheumatism bone disease patient was in
The trend increasing year by year, brings to the live and work of patient greatly painful and worried, also brings to family endless
Disaster.
Rheumatism bone disease is touching difficult chronic systemic disease more, especially higher with the between twenty and fifty incidence of disease（80% patient age
At 20 years old -- 45 years old）.There is following clinical manifestation：
First, when initial, onset is slow, to the lassitude and weak of some months in patient's several weeks before this, loses weight, anorexia, low-heat
With premonitory symptoms such as numb in every limb shouting pains.
2nd, subsequently there is arthralgia, stiff, automatically and passive movement all causes pain for enlargement surrounding skin warm, flush
Bitterly.Start one, two joint involvement, often migrans.
3rd, develop into symmetry panarthritis to start to involve other joints again from the Minor articulus of distal limbs later.Secondly
For metacarpophalangeal, toe, wrist, knee, elbow, ankle, shoulder and hip joint etc., daystart anchylosis, DOMS.
4th, with the development of rheumatism, rheumatoid arthritis pathology, patient irregularly generates heat, and pulse is accelerated, notable anaemia,
Joint becomes stiff and lopsided, leads to maimed person.Knee, elbow, finger, wrist become fixing and bend position, and finger becomes subluxation laterally, and patient loses
Remove self care ability, all day not from bedding it is impossible to move and angor.
The pathogenic factor of rheumatism bone disease：One is bacterium factors, and two is viral factor, and three is inherent cause, and four is sex hormone
Deng for main cause.Often with cold, humidity, fatigue, malnutrition, wound, mental element etc. for this sick risk factor.
The medicine of existing treatment rheumatism bone disease mainly has Western medicine and Chinese medicine, but the treatment cycle of Chinese medicine is longer, preparation
Time is long, and mouthfeel is poor, and a lot of people are difficult to adhere to, therapeutic effect is poor；And existing Western medicine there is also a lot of shortcomings：Poison
Large side effects, high cost, preparation method is complicated, and can not thoroughly effect a radical cure, and easily recurs, have impact on the life of people.
Content of the invention
It is an object of the invention to provide a kind of Western medicine compound treating rheumatism bone disease, to solve in above-mentioned background technology
The problem proposing.
For achieving the above object, the present invention provides following technical scheme：
A kind of Western medicine compound treating rheumatism bone disease, is made up of the raw material of following parts by weight：VX-478 2-15 part, first ammonia
Pterin 0.1-1 part, oxaliplatin formula mannitol injection liquid 1-3 part, phosphodiesterase 0.1-1 part, glucocorticoid medicine 1-5
Part, benefit match general 0.5-2 part, physiological saline 10-50 part, bone peptide piece 0.5-1 part, gelatin powder 1-3 part, steroids 0.1-1 part, mountain Liang
Henbane alkali 1-3 part.
As the further scheme of the present invention：It is made up of the raw material of following parts by weight：VX-478 5-10 part, first ammonia butterfly
Purine 0.1-0.5 part, oxaliplatin formula mannitol injection liquid 2-2.5 part, phosphodiesterase 0.2-0.5 part, glucocorticoid medicine
2-4 part, benefit match general 0.8-1 part, physiological saline 11-45 part, bone peptide piece 0.8-1 part, gelatin powder 2-3 part, steroids 0.1-0.5
Part, anisodamine 1.5-2.5 part.
As the present invention further scheme：It is made up of the raw material of following parts by weight：8 parts of VX-478, first ammonia butterfly
0.4 part of purine, 2.2 parts of oxaliplatin formula mannitol injection liquid, 0.3 part of phosphodiesterase, 3 parts of glucocorticoid medicine, benefit match are general
0.9 part, 40 parts of physiological saline, 0.9 part of bone peptide piece, 2.5 parts of gelatin powder, 0.3 part of steroids, 2 parts of anisodamine.
A kind of preparation method of the Western medicine compound treating rheumatism bone disease, preparation process is as follows：
（1）Weigh each raw material first, standby；
（2）By VX-478, methotrexate (MTX), phosphodiesterase, glucocorticoid medicine, benefit match general, bone peptide piece, steroids,
Anisodamine is put in micronizer and is pulverized, and the 100-500 mesh that sieves；
（3）By physiological saline and gelatin powder mixing, stir；
（4）By step（2）Gains are mixed with oxaliplatin formula mannitol injection liquid, stir 20-50min using mixer；
（5）By step（4）Gains are dried at a temperature of 55-70 DEG C, then utilize micronizer to pulverize, sieve 200-500
Mesh；
（6）By step（5）Gains put into step（3）In gains, obtain softwood；
（7）Above-mentioned soft ability compressing tablet is pelletized, obtains the tablet that grain is 1-2g again；
（8）Above-mentioned tablet is placed 2-5h in -5-5 DEG C of household freezer, obtains final product Western medicine compound.
As the present invention further scheme：Described step（5）By step（4）Gains are dried at a temperature of 60 DEG C,
Then micronizer is utilized to pulverize, sieve 300 mesh.
As the present invention further scheme：Described step（8）Above-mentioned tablet is placed 3h in -3 DEG C of household freezer,
Obtain final product Western medicine compound.
Compared with prior art, the invention has the beneficial effects as follows：
This Western medicine compound passes through raw material and compounds to play synergy, has that toxic and side effect is little, low cost, is not in complication
Advantage, thoroughly can effect a radical cure rheumatism bone disease, and be not easy recur；This Western medicine compound preparation method is simple, and treatment cycle is short, treats
Imitate, be one kind safely and effectively medicine, protect the health of people.
Specific embodiment
With reference to specific embodiment, the technical scheme of this patent is described in more detail.
Embodiment 1
A kind of Western medicine compound treating rheumatism bone disease, is made up of the raw material of following parts by weight：2 parts of VX-478, first ammonia butterfly
0.1 part of purine, 1 part of oxaliplatin formula mannitol injection liquid, 0.1 part of phosphodiesterase, 1 part of glucocorticoid medicine, benefit match general 0.5
Part, 10 parts of physiological saline, 0.5 part of bone peptide piece, 1 part of gelatin powder, 0.1 part of steroids, 1 part of anisodamine.
A kind of preparation method of the Western medicine compound treating rheumatism bone disease, preparation process is as follows：
（1）Weigh each raw material first, standby；
（2）By VX-478, methotrexate (MTX), phosphodiesterase, glucocorticoid medicine, benefit match general, bone peptide piece, steroids,
Anisodamine is put in micronizer and is pulverized, and 100 mesh that sieve；
（3）By physiological saline and gelatin powder mixing, stir；
（4）By step（2）Gains are mixed with oxaliplatin formula mannitol injection liquid, stir 20min using mixer；
（5）By step（4）Gains are dried at a temperature of 55 DEG C, then utilize micronizer to pulverize, sieve 200 mesh；
（6）By step（5）Gains put into step（3）In gains, obtain softwood；
（7）Above-mentioned soft ability compressing tablet is pelletized, obtains the tablet that grain is 1g again；
（8）Above-mentioned tablet is placed 2h in -5 DEG C of household freezer, obtains final product Western medicine compound.
Embodiment 2
A kind of Western medicine compound treating rheumatism bone disease, is made up of the raw material of following parts by weight：15 parts of VX-478, first ammonia butterfly
1 part of purine, 3 parts of oxaliplatin formula mannitol injection liquid, 1 part of phosphodiesterase, 5 parts of glucocorticoid medicine, general 2 parts of benefit match, life
50 parts of salt solution of reason, 1 part of bone peptide piece, 3 parts of gelatin powder, 1 part of steroids, 3 parts of anisodamine.
A kind of preparation method of the Western medicine compound treating rheumatism bone disease, preparation process is as follows：
（1）Weigh each raw material first, standby；
（2）By VX-478, methotrexate (MTX), phosphodiesterase, glucocorticoid medicine, benefit match general, bone peptide piece, steroids,
Anisodamine is put in micronizer and is pulverized, and 500 mesh that sieve；
（3）By physiological saline and gelatin powder mixing, stir；
（4）By step（2）Gains are mixed with oxaliplatin formula mannitol injection liquid, stir 50min using mixer；
（5）By step（4）Gains are dried at a temperature of 70 DEG C, then utilize micronizer to pulverize, sieve 500 mesh；
（6）By step（5）Gains put into step（3）In gains, obtain softwood；
（7）Above-mentioned soft ability compressing tablet is pelletized, obtains the tablet that grain is 2g again；
（8）Above-mentioned tablet is placed 5h in 5 DEG C of household freezer, obtains final product Western medicine compound.
Embodiment 3
A kind of Western medicine compound treating rheumatism bone disease, is made up of the raw material of following parts by weight：8 parts of VX-478, first ammonia butterfly
0.4 part of purine, 2.2 parts of oxaliplatin formula mannitol injection liquid, 0.3 part of phosphodiesterase, 3 parts of glucocorticoid medicine, benefit match are general
0.9 part, 40 parts of physiological saline, 0.9 part of bone peptide piece, 2.5 parts of gelatin powder, 0.3 part of steroids, 2 parts of anisodamine.
A kind of preparation method of the Western medicine compound treating rheumatism bone disease, preparation process is as follows：
（1）Weigh each raw material first, standby；
（2）By VX-478, methotrexate (MTX), phosphodiesterase, glucocorticoid medicine, benefit match general, bone peptide piece, steroids,
Anisodamine is put in micronizer and is pulverized, and 200 mesh that sieve；
（3）By physiological saline and gelatin powder mixing, stir；
（4）By step（2）Gains are mixed with oxaliplatin formula mannitol injection liquid, stir 30min using mixer；
（5）By step（4）Gains are dried at a temperature of 60 DEG C, then utilize micronizer to pulverize, sieve 300 mesh；
（6）By step（5）Gains put into step（3）In gains, obtain softwood；
（7）Above-mentioned soft ability compressing tablet is pelletized, obtains the tablet that grain is 2g again；
（8）Above-mentioned tablet is placed 3h in -3 DEG C of household freezer, obtains final product Western medicine compound.
Comparative example 1
A kind of Western medicine compound treating rheumatism bone disease, is made up of the raw material of following parts by weight：0.4 part of methotrexate (MTX), sand difficult to understand
2.2 parts of sharp platinum formula mannitol injection liquid, 0.3 part of phosphodiesterase, 3 parts of glucocorticoid medicine, benefit match general 0.9 part, physiology salt
40 parts of water, 0.9 part of bone peptide piece, 2.5 parts of gelatin powder, 0.3 part of steroids, 2 parts of anisodamine.
A kind of preparation method of the Western medicine compound treating rheumatism bone disease, preparation process is as follows：
（1）Weigh each raw material first, standby；
（2）Methotrexate (MTX), phosphodiesterase, glucocorticoid medicine, benefit match general, bone peptide piece, steroids, anisodamine are put
Enter in micronizer and pulverize, and 300 mesh that sieve；
（3）By physiological saline and gelatin powder mixing, stir；
（4）By step（2）Gains are mixed with oxaliplatin formula mannitol injection liquid, stir 30min using mixer；
（5）By step（4）Gains are dried at a temperature of 60 DEG C, then utilize micronizer to pulverize, sieve 400 mesh；
（6）By step（5）Gains put into step（3）In gains, obtain softwood；
（7）Above-mentioned soft ability compressing tablet is pelletized, obtains the tablet that grain is 2g again；
（8）Above-mentioned tablet is placed 3h in -3 DEG C of household freezer, obtains final product Western medicine compound.
Experimental example
Diagnostic criteria：Western medicine diagnostic criteria is tamed and dociled with reference to yellow family《Surgery》, according to medical history, sign, conventional roentgenogram and CT examination
Judge.Tcm diagnosis standard is with reference to Tibetan medicine《Four doctor's allusion quotations》.
Experimental subjects：Choose 200 patients meeting above-mentioned standard, 15 years old -75 years old age.Wherein the male sex accounts for 105, female
Property accounts for 95；Wherein cervical spondylopathy 40, lumbar vertebrae hyperosteogeny 40, lumbar vertebrae hyperosteogeny merges waist and takes off 20, and simple waist takes off 30
Example, articulatio genus hyperosteogeny 10, scapulohumeral periarthritis 30, with osteoproliferation 30.It is divided into four groups, i.e. 1 group of embodiment, embodiment 2
Group, 3 groups of embodiment and comparative example group, every group of 50 patients, four groups are compared no in sides such as sex, age, the course of disease, state of an illness scorings
Significant difference (P ＞ 0.05), has comparativity.
1 group of the embodiment Western medicine compound that daily prepared by embodiment 1, daily prepared by embodiment 2 for 2 groups of embodiment
Western medicine compound, 3 groups of embodiment daily embodiment 3 preparation Western medicine compound, comparative example group daily comparative example 1
The Western medicine compound of preparation.Twice daily, take in the morning and evening, after meal half an hour take, 7 days be a course for the treatment of.
Criterion of therapeutical effect
Effective：After taking 2 courses for the treatment of, clinical symptom disappearance, limb activity freely, is taken care of oneself.
Effectively：After taking 3 courses for the treatment of, clinical symptoms disappear substantially, and limb activity freely, can substantially take care of oneself by life.
Invalid：After taking 1 course for the treatment of, with treatment before be not improved or increase.
Treatment results see table：
| Project | Number of cases/example | Effective/example | Effectively/example | Invalid/example | Efficient/% |
| 1 group of embodiment | 50 | 20 | 29 | 1 | 98 |
| 2 groups of embodiment | 50 | 21 | 29 | 0 | 100 |
| 3 groups of embodiment | 50 | 30 | 20 | 0 | 100 |
| Comparative example group | 50 | 13 | 18 | 19 | 62 |
It is not added with VX-478 in comparative example 1.By upper table as can be seen that interpolation VX-478 can be notable in embodiment 1-3
Improve the curative effect that this Western medicine compound treats rheumatism bone disease, synergy has been played by drug regimen；And do not occur in observing
Bad reaction and complication, the blood of two groups of patients, urine, stool routine and hepatic and renal function inspection after treatment end is showed no exception.
This Western medicine compound passes through raw material and compounds to play synergy, has that toxic and side effect is little, low cost, is not in simultaneously
The advantage sending out disease, thoroughly can effect a radical cure rheumatism bone disease, and is not easy to recur；This Western medicine compound preparation method is simple, treatment cycle
Short, good effect, it is one kind safely and effectively medicine, protect the health of people.
Above the better embodiment of this patent is explained in detail, but this patent is not limited to above-mentioned embodiment party
Formula, in the ken that one skilled in the relevant art possesses, can also be on the premise of without departing from this patent objective
Make a variety of changes.
Claims (6)
1. a kind of Western medicine compound treating rheumatism bone disease is it is characterised in that be made up of the raw material of following parts by weight：Peace Pune
Wei 2-15 part, methotrexate (MTX) 0.1-1 part, oxaliplatin formula mannitol injection liquid 1-3 part, phosphodiesterase 0.1-1 part, sugared cortical hormone
Plain class medicine 1-5 part, benefit match general 0.5-2 part, physiological saline 10-50 part, bone peptide piece 0.5-1 part, gelatin powder 1-3 part, steroids
0.1-1 part, anisodamine 1-3 part.
2. the Western medicine compound for the treatment of rheumatism bone disease according to claim 1 is it is characterised in that by following parts by weight
Raw material forms：VX-478 5-10 part, methotrexate (MTX) 0.1-0.5 part, oxaliplatin formula mannitol injection liquid 2-2.5 part, di(2-ethylhexyl)phosphate
Esterase 0.2-0.5 part, glucocorticoid medicine 2-4 part, benefit match general 0.8-1 part, physiological saline 11-45 part, bone peptide piece 0.8-1
Part, gelatin powder 2-3 part, steroids 0.1-0.5 part, anisodamine 1.5-2.5 part.
3. the Western medicine compound for the treatment of rheumatism bone disease according to claim 1 is it is characterised in that by following parts by weight
Raw material forms：8 parts of VX-478,0.4 part of methotrexate (MTX), 2.2 parts of oxaliplatin formula mannitol injection liquid, 0.3 part of phosphodiesterase,
3 parts of glucocorticoid medicine, general 0.9 part of benefit match, 40 parts of physiological saline, 0.9 part of bone peptide piece, 2.5 parts of gelatin powder, steroids
0.3 part, 2 parts of anisodamine.
4. a kind of preparation method of the described Western medicine compound for the treatment of rheumatism bone disease as arbitrary in claim 1-3, its feature exists
In preparation process is as follows：
（1）Weigh each raw material first, standby；
（2）By VX-478, methotrexate (MTX), phosphodiesterase, glucocorticoid medicine, benefit match general, bone peptide piece, steroids,
Anisodamine is put in micronizer and is pulverized, and the 100-500 mesh that sieves；
（3）By physiological saline and gelatin powder mixing, stir；
（4）By step（2）Gains are mixed with oxaliplatin formula mannitol injection liquid, stir 20-50min using mixer；
（5）By step（4）Gains are dried at a temperature of 55-70 DEG C, then utilize micronizer to pulverize, sieve 200-500
Mesh；
（6）By step（5）Gains put into step（3）In gains, obtain softwood；
（7）Above-mentioned soft ability compressing tablet is pelletized, obtains the tablet that grain is 1-2g again；
（8）Above-mentioned tablet is placed 2-5h in -5-5 DEG C of household freezer, obtains final product Western medicine compound.
5. the preparation method of the Western medicine compound for the treatment of rheumatism bone disease according to claim 4 is it is characterised in that described step
Suddenly（5）By step（4）Gains are dried at a temperature of 60 DEG C, then utilize micronizer to pulverize, sieve 300 mesh.
6. the preparation method of the Western medicine compound for the treatment of rheumatism bone disease according to claim 4 is it is characterised in that described step
Suddenly（8）Above-mentioned tablet is placed 3h in -3 DEG C of household freezer, obtains final product Western medicine compound.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611078004.7A CN106390131A (en) | 2016-11-30 | 2016-11-30 | Western medicine composition for treating rheumatic bone disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611078004.7A CN106390131A (en) | 2016-11-30 | 2016-11-30 | Western medicine composition for treating rheumatic bone disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106390131A true CN106390131A (en) | 2017-02-15 |
Family
ID=58083973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611078004.7A Pending CN106390131A (en) | 2016-11-30 | 2016-11-30 | Western medicine composition for treating rheumatic bone disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106390131A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103271961A (en) * | 2013-06-14 | 2013-09-04 | 石远杲 | Preparation for treating rheumatic bone diseases |
| CN104096221A (en) * | 2014-07-31 | 2014-10-15 | 杜志政 | Natural drug composition for curing rheumatism bone diseases and preparation method thereof |
| CN105288565A (en) * | 2015-11-30 | 2016-02-03 | 姜辉阳 | Traditional Chinese medicine composition for treating rheumatoid bone diseases |
| CN105311210A (en) * | 2015-12-02 | 2016-02-10 | 隋妍蕾 | Pharmaceutical composition for treating rheumatoid bone diseases |
-
2016
- 2016-11-30 CN CN201611078004.7A patent/CN106390131A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103271961A (en) * | 2013-06-14 | 2013-09-04 | 石远杲 | Preparation for treating rheumatic bone diseases |
| CN104096221A (en) * | 2014-07-31 | 2014-10-15 | 杜志政 | Natural drug composition for curing rheumatism bone diseases and preparation method thereof |
| CN105288565A (en) * | 2015-11-30 | 2016-02-03 | 姜辉阳 | Traditional Chinese medicine composition for treating rheumatoid bone diseases |
| CN105311210A (en) * | 2015-12-02 | 2016-02-10 | 隋妍蕾 | Pharmaceutical composition for treating rheumatoid bone diseases |
Non-Patent Citations (4)
| Title |
|---|
| 孙凌云主编: "《类风湿关节炎自我保健上上策》", 31 December 2013, 江苏科学技术出版社 * |
| 徐军主编: "《类风湿关节炎防治问答》", 31 December 2015, 金盾出版社 * |
| 潘卫三主编: "《工业药剂学 第3版》", 31 August 2015, 中国医药科技出版社 * |
| 陈长青等主编: "《关节疼痛怎么办》", 30 April 2015, 金盾出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102091289B (en) | Traditional Chinese medicine preparation for treating acute and chronic soft tissue injuries | |
| CN100548343C (en) | A kind of medicine and preparation technology thereof who treats Feng Han Shi Paralysis, hyperosteogeny, intervertebral disk hernia | |
| CN104491828B (en) | A kind of temperature leads to Traditional Chinese medicine used as analgesic preparation and its paste preparation method | |
| CN106390131A (en) | Western medicine composition for treating rheumatic bone disease | |
| CN104225061B (en) | A kind of Chinese medicine treating type of deficiency of both QI and YIN viral myocarditis | |
| CN106421783A (en) | Western medicinal composition for treating rheumatism and preparation method of western medicinal composition | |
| CN101757311A (en) | Traditional Chinese medicine capsule for treating knee osteoarthritis | |
| CN106729704A (en) | A kind of Western medicine compound for treating rheumatism bone disease | |
| CN110507796A (en) | A kind of Chinese medicine preparation for treating a variety of diseases | |
| CN101249236B (en) | Chinese and western medicine combined preparations for curing epileptic | |
| CN104547591A (en) | Pharmaceutical composition for treating acute ankle sprain | |
| CN109865010A (en) | The liquid medicine and preparation method thereof for treating rheumatic arthritis, osteoproliferation and protrusion of lumber intervertebral disc | |
| CN103271961A (en) | Preparation for treating rheumatic bone diseases | |
| Reeder et al. | Extensor indicis proprius syndrome secondary to an anomalous extensor indicis proprius muscle belly | |
| CN111450195B (en) | Traditional Chinese medicine composition for treating heat arthralgia | |
| CN108143799B (en) | Traditional Chinese medicine composition for treating brucellosis and preparation method thereof | |
| CN105125704B (en) | A kind of compositions purposes in the medicine of preparation treatment gout | |
| Shreeve | The alternative dictionary of symptoms and cures | |
| Xiaohui et al. | On the effect of the application of traditional Chinese medicine to umbilicus with timing point massage on improving gastrointestinal function and satisfaction degree of bedridden patients in department of orthopedics | |
| CN1313110C (en) | Oteoproliferation treating plaster and preparation method thereof | |
| CN105770687A (en) | Preparation method and application of anorexia patch | |
| CN103251851B (en) | Internal and external traditional Chinese medicine formulation for treating rheumatic and rheumatoid diseases | |
| CN105288325A (en) | Traditional Chinese medicine for treating arrhythmia caused by deficiency of both vital energy and yin | |
| CN104840624A (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis and preparation method thereof | |
| Chen | Acupuncture combined with tuina treatment for infantile diarrhea |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170215 |